Business
Inspira™ Releases New Data Demonstrating Superiority of its Core Technology, Across Key Endpoints of HMSS Indicator
An unprecedented achievement of a zero pressure gradient measured when using the VORTX™ device, directly correlating with a decrease in markers of blood
About this update from Qtrex Quantum Ltd.
[{"type":"text","content":"An unprecedented achievement of a zero pressure gradient measured when using the VORTX™ device, directly correlating with a decrease in markers of blood damage.The performance of the VORTX™, tested according to a regulatory guideline, was found to meet 100% of blood oxygenation requirements at various blood flow rates.A significant leap forward in the development of safer, more effective medical devices designed to minimize patient risk and improve clinical outcomes.U.S. Patent with 94% of claims found to be novel.RA'ANANA, Israel, March 12, 2024 /PRNewswire/ -- Inspira™Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) (the \"Company\" or \"Inspira Technologies\"), a breakthrough medical technology company targeting to supersede mechanical ventilators, today announced that the Company's U.S. patent backed technology, the orbiting blood oxygenation technology (VORTX™) has broken through a significant technological barrier, meeting 100% of regulatory guideline requirements for blood oxygenation and carbon dioxide removal, at various blood flow rates with the pressure gradient on the blood across the device remaining at zero level. Pressure gradient is associated with high mechanical shear stress (HMSS), which plays a dominant role in damaging blood components such as red blood cells, immune cells, thrombocytes and more. These primary results for the key endpoints of a new blood oxygenation technology without the need for fiber membranes and with zero levels of pressure gradient mark a huge milestone for the Company and for the INSPIRA™ ART (Gen 2) device.\n\nThe Chief Technology Officer of Inspira Technologies, Dr. Daniella Yeheskely-Hayon, stated: \"Our team achieved this technological breakthrough with the Company's proprietary orbiting oxygenation technology designed to promote less damaging blood flow regime and eliminate the need to use the current membrane fibers-based devices that are associated with increased pressure differential and high shear stress across the blood oxygenators, which leads to severe critical clinical complications such as hemolysis, bleeding, inflammation and blood clots. For me, this is a very significant day in my career as a scientist.\"\nThe advanced experiments demonstrated the primary performance of the VORTX™ by collecting data on oxygenation, carbon dioxide removal, and pressures across the de...